Achieving Efficacy and Exploring Indication Expansion for Complement Inhibitors
The complement community is shifting gear, with more companies than ever targeting alternative complement proteins for their therapies, allowing for a larger range of diseases to be targeted.
With more assets in ophthalmology, neurology, and oncology than ever before, the complement-based therapeutics field has everyone asking the same question: which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies?
From the discovery of new pathways to target to post-approval indication expansion, the immunology landscape is primed to capitalize on the huge strides being taken in achieving efficacy and approving the safety profile of complement-based therapeutics.
Join 100+ complement industry leaders, scientists, and clinicians at the premier, end-to-end 8th Complement-Based Drug Development Summit to shape the future of complement-targeted therapies.
The complement community is shifting gear, with more companies than ever targeting alternative complement proteins for their therapies, allowing for a larger range of diseases to be targeted.
With more assets in ophthalmology, neurology, and oncology than ever before, the complement-based therapeutics field has everyone asking the same question: which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies?
From the discovery of new pathways to target to post-approval indication expansion, the immunology landscape is primed to capitalize on the huge strides being taken in achieving efficacy and approving the safety profile of complement-based therapeutics.
Join 100+ complement industry leaders, scientists, and clinicians at the premier, end-to-end 8th Complement-Based Drug Development Summit to shape the future of complement-targeted therapies.
